Genmab(GMAB)

搜索文档
Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline
Invezz· 2025-09-29 07:23
Denmark's Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotechnology company, in an all-cash transaction valued at $8 billion, the companies announced on Monday. The deal marks a significant expansion of Genmab's oncology portfolio, adding a promising late-stage cancer therapy candidate to its pipeline. ...
Genmab to buy Dutch cancer drugmaker Merus for $8 billion
Reuters· 2025-09-29 05:19
Denmark's Genmab has agreed to acquire Merus NV , a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, for $8 billion in cash, the two companies said on Monday. ...
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Globenewswire· 2025-09-29 05:08
Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab ...
Genmab nearing deal to acquire Merus (GMAB:NASDAQ)
Seeking Alpha· 2025-09-28 23:58
Danish biotech Genmab (GMAB) is in advanced discussions to acquire Merus (NASDAQ:MRUS), a Dutch drug developer targeting head and neck cancer, Bloomberg News reported on Sunday, citing people familiar with the matter. Having received takeover interest from several large biopharma ...
Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Seeking Alpha· 2025-09-25 07:17
PresentationThank you so much for joining. My pleasure to be hosting Anthony Pagano, CFO of Genmab. We have 40 minutes. I think, Anthony will make some introductory comments, and then we'll get into questions. Anthony, with pleasure, over to you.Anthony PaganoExecutive VP & CFO Great. Thank you. Pleasure to be back at the conference today, Sachin. Pleasure to have a chance to catch up with you and all of the investors today. As we sit here in September of 2025, and just reflecting on the progress in the fi ...
Bernstein Reiterates a Sell Rating on Genmab A/S (GMAB)
Insider Monkey· 2025-09-17 18:27
人工智能能源需求 - 人工智能是史上最耗电的技术 每个数据中心耗电量相当于一个小型城市 [2] - 人工智能查询和模型更新消耗巨大能量 正在将全球电网推向崩溃边缘 [1][2] - OpenAI创始人警告人工智能未来取决于能源突破 埃隆马斯克预测明年将出现电力短缺 [2] 能源基础设施机会 - 一家鲜为人知的公司拥有关键能源基础设施资产 将受益于人工智能能源需求激增 [3] - 该公司定位为人工智能能源繁荣的"收费亭"运营商 从每度出口电力中收取费用 [4] - 公司涉及液化天然气出口领域 该行业将在特朗普"美国优先"能源政策下爆发性增长 [7] 公司业务优势 - 公司拥有关键核能基础设施资产 处于美国下一代电力战略核心位置 [7] - 是全球少数能执行大型复杂EPC项目的企业 涵盖油气、可再生燃料和工业基础设施 [7] - 公司完全无负债 持有相当于市值近三分之一的现金储备 [8] - 交易估值低于7倍市盈率(扣除现金和投资) 持有另一家人工智能热门公司的重大股权 [9][10] 多重增长动力 - 同时受益于人工智能基础设施超级周期、特朗普关税推动的回流浪潮、美国液化天然气出口激增 [14] - 在核能领域拥有独特布局 核能是未来清洁可靠电力的发展方向 [14] - 公司业务覆盖人工智能、能源、关税和回流四大趋势 形成协同效应 [6]
Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy (NASDAQ:GMAB)
Seeking Alpha· 2025-09-14 12:31
Genmab A/S ( GMAB ) stock is experiencing its best month so far with double-digit gains, and it appears to be the best so far this year. The growth might be coming from an excellent H1 2025Gamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu has a proven track record of providing ac ...
Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy
Seeking Alpha· 2025-09-14 12:31
Genmab A/S ( GMAB ) stock is experiencing its best month so far with double-digit gains, and it appears to be the best so far this year. The growth might be coming from an excellent H1 2025Gamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu has a proven track record of providing ac ...
Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff
Seeking Alpha· 2025-09-12 17:58
分析师背景与方法论 - 分析师Stephen拥有注册护士和工商管理硕士背景 专注于通过投资流程设计分析医疗保健和科技行业股票 [1] - 其研究采用专有的"Dizzy Framework"方法论 旨在规避追逐市场噪音或固守先验观点等常见行为错误 [1] - 该框架注重信息质量与时效性 强调耐心与纪律性投资 将复杂科学及市场动态转化为可操作的投资论点 [1] 研究理念与影响 - 分析方法受到《超预测》和《随机漫步的傻瓜》两本著作的显著影响 [1] - 研究过程强调概率性分析而非绝对确定性 反映在预测与观点形成中 [3] 信息披露 - 分析师未持有任何提及公司的股票、期权或衍生品头寸 且未来72小时内无开仓计划 [2] - 分析内容为作者个人观点 未获得除Seeking Alpha外任何形式的报酬 [2] - 与所提及股票公司不存在业务关联关系 [2] 内容性质说明 - 文章旨在提供信息内容 不应被视为对公司的详尽分析 [3] - 不构成个性化投资建议 不包含明确的买入/卖出/持有/做空/做多推荐 [3] - 建议投资者独立验证信息并自行开展研究 [3]
Genmab: A Matter Of Time
Seeking Alpha· 2025-09-12 10:15
投资平台服务 - 平台专注于增长型股票和生物科技股票的投资机会 提供具有吸引力的风险回报比的投资组合和观察名单 并密切跟踪这些股票的表现 [1] - 平台提供包含15至20只股票且定期更新的模型投资组合 以及包含最多10只预期当年表现优异股票的优选名单 [2] - 平台提供针对短期和中期市场波动的交易策略 并设有社区聊天功能供投资者交流和提问 [2] 分析师持仓披露 - 分析师通过股票持有、期权或其他衍生品方式对GMAB公司持有长期多头头寸 [3]